ABBV
AbbVie Inc.
Pharmaceutical company with focus on immunology and virology. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
13 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
ABBV has an insider buy conviction of 50%, compared to the Pharmaceuticals sector buy average of 50%. ABBV ranks #1 in insider activity out of 2 tracked companies in its industry.
Multiple Insiders
S - Sale+OE Insiders
$0 total
Over the last 90 days, corporate insiders at AbbVie Inc. (ABBV) engaged in a total of 13 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for ABBV shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale+OE Insiders), who traded 74.4K shares valued at $0 on Aug 14, 2026.
Quick Actions
Explore Peers in Drug Manufacturers
Compare insider activity and sentiment scores across similar organizations.
FAQs About AbbVie Inc. Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ABBV.